But the digital-first promise carried a blind spot: it solves for tasks, not emotions. Patients don’t start, stay on, or ...

Vossman discusses the genomics landscape, as well as next-generation sequencing (or NGS), and the Model Project, a ...

AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US in light of FDA concerns ...

It's notable that Ipsen has bolted on more than 20 early-stage programmes since 2020 as part of a push to become a major ...

Yet, many medical affairs teams remain bound to traditional workflows. Linear processes and siloed functions are struggling ...

"Our goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer whose tumours stopped ...

US companies Amgen, Bristol Myers Squibb, Gilead Sciences, and Merck/MSD have signed up to reduce the prices of medicines for ...

In 2025, women’s health moved from recognition to getting foundations in place, with new funding vehicles, national ...

While everyone agrees on the ethical imperative to reduce animal use, the challenge of widespread readiness will depend on partnership, proof, and continued development activities. Public perception ...

Combined, the two drugs made revenues of nearly $600 million in the last four quarters, while BioMarin has forecast that its ...

Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing down the progression of Parkinson's disease. The results of the phase 2 ...

Sio Gene Therapies' litany of clinical disappointments over the last few years has finally led to the demise of the biotech, formerly known as Axovant and one of the 'vant' companies originally ...